Survival Prospects and Circumstances of Death in Contemporary Adult Congenital Heart Disease Patients Under Follow-Up at a Large Tertiary Centre

Background— Adult congenital heart disease (ACHD) patients have ongoing morbidity and reduced long-term survival. Recently, the importance of specialized follow-up at tertiary ACHD centers has been highlighted. We aimed to assess survival prospects and clarify causes of death in a large cohort of patients at a single, tertiary center. Methods and Results— We included 6969 adult patients (age 29.9±15.4 years) under follow-up at our institution between 1991 and 2013. Causes of death were ascertained from official death certificates. Survival was compared with the expected survival in the general age- and sex-matched population, and standardized mortality rates were calculated. Over a median follow-up time of 9.1 years (interquartile range, 5.2–14.5), 524 patients died. Leading causes of death were chronic heart failure (42%), pneumonia (10%), sudden-cardiac death (7%), cancer (6%), and hemorrhage (5%), whereas perioperative mortality was comparatively low. Isolated simple defects exhibited mortality rates similar to those in the general population, whereas patients with Eisenmenger syndrome, complex congenital heart disease, and Fontan physiology had much poorer long-term survival (P<0.0001 for all). The probability of cardiac death decreased with increasing patient’s age, whereas the proportion of patients dying from noncardiac causes, such as cancer, increased. Conclusions— ACHD patients continue to be afflicted by increased mortality in comparision with the general population as they grow older. Highest mortality rates were observed among patients with complex ACHD, Fontan physiology, and Eisenmenger syndrome. Our data provide an overview over causes of mortality and especially the spectrum of noncardiac causes of death in contemporary ACHD patients.

[1]  M. Abrahamowicz,et al.  Specialized Adult Congenital Heart Disease Care: The Impact of Policy on Mortality , 2014, Circulation.

[2]  K. Dimopoulos,et al.  Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. , 2014, European heart journal.

[3]  D. Grobbee,et al.  Heart failure admissions in adults with congenital heart disease; risk factors and prognosis. , 2013, International journal of cardiology.

[4]  A. Zwinderman,et al.  Effect of Valsartan on Systemic Right Ventricular Function: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial , 2013, Circulation.

[5]  D. Grobbee,et al.  Circumstances of death in adult congenital heart disease. , 2012, International journal of cardiology.

[6]  E. Mariman,et al.  Mortality in adult congenital heart disease: are national registries reliable for cause of death? , 2011, International journal of cardiology.

[7]  J. Afilalo,et al.  Geriatric congenital heart disease: burden of disease and predictors of mortality. , 2011, Journal of the American College of Cardiology.

[8]  Helmut Baumgartner,et al.  ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). , 2010, European heart journal.

[9]  W. Budts,et al.  Temporal Trends in Survival to Adulthood Among Patients Born With Congenital Heart Disease From 1970 to 1992 in Belgium , 2010, Circulation.

[10]  M. Abrahamowicz,et al.  Changing mortality in congenital heart disease. , 2010, Journal of the American College of Cardiology.

[11]  D. Grobbee,et al.  Mortality in adult congenital heart disease. , 2010, European heart journal.

[12]  Kanaka D. Shetty,et al.  Mortality associated with adult congenital heart disease: Trends in the US population from 1979 to 2005. , 2009, American heart journal.

[13]  L. Harris,et al.  Implantable Cardioverter-Defibrillators in Tetralogy of Fallot , 2008, Circulation.

[14]  H. Sairanen,et al.  Causes of late deaths after pediatric cardiac surgery: a population-based study. , 2007, Journal of the American College of Cardiology.

[15]  D. Pennell,et al.  Ventricular Fibrosis Suggested by Cardiovascular Magnetic Resonance in Adults With Repaired Tetralogy of Fallot and Its Relationship to Adverse Markers of Clinical Outcome , 2006, Circulation.

[16]  P. Engelfriet,et al.  The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. , 2005, European heart journal.

[17]  M. Gatzoulis,et al.  Towards defining heart failure in adults with congenital heart disease. , 2004, International journal of cardiology.

[18]  D. Pennell,et al.  Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study. , 2004, International journal of cardiology.

[19]  V. Coviello,et al.  Cumulative Incidence Estimation in the Presence of Competing Risks , 2004 .

[20]  Alona Muzikansky,et al.  Re: Selective Inhibition of Her2-positive Breast Cancer Cells by the Hiv Protease Inhibitor Nelfinavir Notes Erratum: " Comparing Survival of a Sample to That of a Standard Population " , 2022 .

[21]  A. Coats,et al.  Congenital heart disease: the original heart failure syndrome. , 2003, European Heart Journal.

[22]  J. Hoffman,et al.  Task force 1: the changing profile of congenital heart disease in adult life. , 2001, Journal of the American College of Cardiology.

[23]  S. Siu,et al.  Mode of death in adults with congenital heart disease. , 2000, The American journal of cardiology.

[24]  S. Siu,et al.  Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study , 2000, The Lancet.

[25]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[26]  M. Gatzoulis Adult congenital heart disease: education, education, education , 2006, Nature Clinical Practice Cardiovascular Medicine.